Terms: = Lung cancer AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF
208 results:
1. Hyaluronic acid-based injectable formulation developed to mitigate metastasis and radiation-induced skin fibrosis in breast cancer treatment.
Wang YC; Shueng PW; Hu CY; Tung FI; Chen MH; Liu TY
Carbohydr Polym; 2024 Jul; 336():122136. PubMed ID: 38670762
[TBL] [Abstract] [Full Text] [Related]
2. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.
van Kooten JP; Dietz MV; Dubbink HJ; Verhoef C; Aerts JGJV; Madsen EVE; von der Thüsen JH
Clin Exp Med; 2024 Apr; 24(1):80. PubMed ID: 38642130
[TBL] [Abstract] [Full Text] [Related]
3. Unraveling the Significance of MET Focal Amplification in lung cancer: Integrative NGS, FISH, and IHC Investigation.
Xiang C; Lv X; Chen K; Guo L; Zhao R; Teng H; Ye M; Kuang T; Hou T; Liu C; Du H; Zhang Z; Han Y
Mod Pathol; 2024 Apr; 37(4):100451. PubMed ID: 38369190
[TBL] [Abstract] [Full Text] [Related]
4. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
Hung YP; Chirieac LR
Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
[TBL] [Abstract] [Full Text] [Related]
5. Identification of protein signatures for lung cancer subtypes based on BPSO method.
Wang J; Wang H; Xu J; Song Q; Zhou B; Shangguan J; Xue M; Wang Y
PLoS One; 2023; 18(12):e0294243. PubMed ID: 38060494
[TBL] [Abstract] [Full Text] [Related]
6. Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.
Nash A; Creaney J
Curr Oncol Rep; 2023 Dec; 25(12):1515-1522. PubMed ID: 38015374
[TBL] [Abstract] [Full Text] [Related]
7. Updates in Management of Malignant Pleural Mesothelioma.
John A; O'Sullivan H; Popat S
Curr Treat Options Oncol; 2023 Dec; 24(12):1758-1789. PubMed ID: 37975977
[TBL] [Abstract] [Full Text] [Related]
8. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
Kondo N; Utsumi T; Shimizu Y; Takemoto A; Oh-Hara T; Uchibori K; Subat-Motoshi S; Ninomiya H; Takeuchi K; Nishio M; Miyazaki Y; Katayama R
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37917191
[TBL] [Abstract] [Full Text] [Related]
9. Whole-Genome Comparative Copy Number Alteration Profiling between Malignant Pleural Mesothelioma and Asbestos-Induced Chronic Pleuritis.
Tuncel T; Metintas M; Güntülü AK; Güneş HV
J Environ Pathol Toxicol Oncol; 2024; 43(1):31-44. PubMed ID: 37824368
[TBL] [Abstract] [Full Text] [Related]
10. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract] [Full Text] [Related]
11. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
[TBL] [Abstract] [Full Text] [Related]
12. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
13. Genetic Pathways in Peritoneal Mesothelioma Tumorigenesis.
Panagopoulos I; Andersen K; Brunetti M; Gorunova L; Davidson B; Lund-Iversen M; Micci F; Heim S
Cancer Genomics Proteomics; 2023; 20(4):363-374. PubMed ID: 37400148
[TBL] [Abstract] [Full Text] [Related]
14. Neutrophil extracellular traps mediate TLR9/merlin axis to resist ferroptosis and promote triple negative breast cancer progression.
Yao L; Sheng X; Dong X; Zhou W; Li Y; Ma X; Song Y; Dai H; Du Y
Apoptosis; 2023 Oct; 28(9-10):1484-1495. PubMed ID: 37368176
[TBL] [Abstract] [Full Text] [Related]
15. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
Borea F; Franczak MA; Garcia M; Perrino M; Cordua N; Smolenski RT; Peters GJ; Dziadziuszko R; Santoro A; Zucali PA; Giovannetti E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298116
[TBL] [Abstract] [Full Text] [Related]
16. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.
Schaefer IM; Mariño-Enríquez A; Hammer MM; Padera RF; Sholl LM
Mod Pathol; 2023 Sep; 36(9):100237. PubMed ID: 37295554
[TBL] [Abstract] [Full Text] [Related]
17. Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations.
Sato T; Akao K; Sato A; Tsujimura T; Mukai S; Sekido Y
Cancer Med; 2023 Jun; 12(12):13586-13598. PubMed ID: 37165917
[TBL] [Abstract] [Full Text] [Related]
18. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract] [Full Text] [Related]
19. Molecular Characterization of Testicular Mesothelioma and the Role of Asbestos as a Causative Factor.
Hocking AJ; Thomas EM; Prabhakaran S; Jolley A; Woods SL; Soeberg MJ; Klebe S
Arch Pathol Lab Med; 2023 Dec; 147(12):1446-1450. PubMed ID: 36800547
[TBL] [Abstract] [Full Text] [Related]
20. Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
Li Y; Yang SR; Chen YB; Adusumilli PS; Bialik A; Bodd FM; Ladanyi M; Lopardo J; Offin MD; Rusch VW; Travis WD; Zauderer MG; Chang JC; Sauter JL
Mod Pathol; 2023 Mar; 36(3):100030. PubMed ID: 36788094
[TBL] [Abstract] [Full Text] [Related]
[Next]
